MX2014002949A - Compuesto de imidazopiridina, composiciones y metodos de uso. - Google Patents

Compuesto de imidazopiridina, composiciones y metodos de uso.

Info

Publication number
MX2014002949A
MX2014002949A MX2014002949A MX2014002949A MX2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A
Authority
MX
Mexico
Prior art keywords
methods
compositions
imidazopyridine compounds
formulas
compound
Prior art date
Application number
MX2014002949A
Other languages
English (en)
Inventor
Birong Zhang
Vickie Hsiao-Wei Tsui
Yingjie Lai
Liangjun
Steven R Magnuson
Kirk D Robarge
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002949A publication Critical patent/MX2014002949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a inhibidores de TYK2 de Fórmulas (la-Ib), estereoisómeros o sales de los mismos farmacéuticamente aceptables, en donde A, X, Ra, R1, R2, R4, R5 y R16 son definidos en la presente, una composición farmacéutica que incluye un compuesto de Fórmula (la-Ib) y un portador, adyuvante o vehículo farmacéuticamente aceptable, y métodos para usar el compuesto o composición en la terapia de enfermedades inflamatorias.
MX2014002949A 2011-09-20 2012-09-19 Compuesto de imidazopiridina, composiciones y metodos de uso. MX2014002949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536932P 2011-09-20 2011-09-20
PCT/EP2012/068380 WO2013041539A1 (en) 2011-09-20 2012-09-19 Imidazopyridine compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2014002949A true MX2014002949A (es) 2014-04-30

Family

ID=46963696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002949A MX2014002949A (es) 2011-09-20 2012-09-19 Compuesto de imidazopiridina, composiciones y metodos de uso.

Country Status (11)

Country Link
US (1) US20140206702A1 (es)
EP (1) EP2758397A1 (es)
JP (1) JP2014526538A (es)
KR (1) KR20140082710A (es)
CN (1) CN103827115A (es)
BR (1) BR112014006643A2 (es)
CA (1) CA2845409A1 (es)
HK (1) HK1198365A1 (es)
MX (1) MX2014002949A (es)
RU (1) RU2014113236A (es)
WO (1) WO2013041539A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
JP2017525734A (ja) 2014-09-02 2017-09-07 ピエール、ファーブル、メディカマン 癌の治療において有用なイソキノリノン誘導体
CN107428753B (zh) 2015-01-17 2020-03-03 珍·X·江 用于治疗原发性癌症和癌症转移的小分子
EP3360864B1 (en) 2015-10-07 2021-04-28 Sumitomo Dainippon Pharma Co., Ltd. Pyrimidine compound
US11400096B2 (en) 2017-10-19 2022-08-02 Board Of Regents, The University Of Texas System Small molecules for the treatment of autoimmune disorders
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ES2166368T3 (es) 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5808110A (en) 1994-07-21 1998-09-15 Akzo Nobel Nv Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
DE69904358T2 (de) 1998-11-19 2003-04-17 Warner Lambert Co N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid, ein irreversibler tyrosin-kinasen hemmer
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2007145957A1 (en) * 2006-06-09 2007-12-21 Merck & Co., Inc. Inhibitors of janus kinases
US7915268B2 (en) * 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
CA2666940A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as pkc-theta inhibitors
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds

Also Published As

Publication number Publication date
HK1198365A1 (en) 2015-04-10
CN103827115A (zh) 2014-05-28
KR20140082710A (ko) 2014-07-02
BR112014006643A2 (pt) 2017-04-04
CA2845409A1 (en) 2013-03-28
US20140206702A1 (en) 2014-07-24
WO2013041539A1 (en) 2013-03-28
RU2014113236A (ru) 2015-10-27
JP2014526538A (ja) 2014-10-06
EP2758397A1 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014002949A (es) Compuesto de imidazopiridina, composiciones y metodos de uso.
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
MX2013011330A (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
JO3111B1 (ar) ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk
MX2013007867A (es) Compuestos de indol o analogos de los mismos utiles para el mismo tratamiento de degeneracion macular relacionada con la edad (amd).
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MX2013012588A (es) Inhibidores de cinasa.
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2013010511A (es) Inhibidores triciclicos de girasa.
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
GB201209587D0 (en) Therapeutic compounds
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX340574B (es) Imidazo pirazinas.
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
MX2013007892A (es) Derivados de fenetilsulfona isoindolina y su uso.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.